James R Runo
Overview
Explore the profile of James R Runo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
504
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Del Valle K, Kay D, Krowka M, Runo J, Sadd C, Heimbach J, et al.
Transplant Direct
. 2025 Feb;
11(3):e1757.
PMID: 39936134
Background: The current model for end-stage liver disease (MELD) exception policies for portopulmonary hypertension (POPH) require serial right heart catheterizations (RHCs) every 3 mo to maintain exception points. RHC is...
2.
Lentine K, Levine D, Runo J, Caliskan Y, Costa S, Lam N, et al.
Turkish J Nephrol
. 2024 Jan;
33(1):8-26.
PMID: 38213512
Pulmonary hypertension (PH) is often present in patients presenting for kidney transplant listing. While PH can complicate kidney transplant (KTx), with multidisciplinary management that includes both the transplant center and...
3.
DuBrock H, Burger C, Bartolome S, Feldman J, Ivy D, Rosenzweig E, et al.
Pulm Circ
. 2022 Dec;
12(4):e12172.
PMID: 36540874
[This corrects the article DOI: 10.1177/20458940211020913.].
4.
Alman K, Sadd C, Ravel A, Raza F, Chybowski A, Runo J
Pulm Circ
. 2022 Aug;
12(3):e12118.
PMID: 36034401
There is little known about performing transcatheter aortic valve replacement (TAVR) in patients with group 1 pulmonary arterial hypertension (PAH) on advanced pulmonary vasodilator therapy. Retrospective cohort study among 90...
5.
Barton G, Corrado P, Francois C, Runo J, Chesler N, McMillan A, et al.
Pulm Circ
. 2022 May;
12(1):e12025.
PMID: 35506091
No abstract available.
6.
DuBrock H, Burger C, Bartolome S, Feldman J, Ivy D, Rosenzweig E, et al.
Pulm Circ
. 2021 Jun;
11(3):20458940211020913.
PMID: 34158918
Compared to idiopathic pulmonary arterial hypertension (IPAH), patients with portopulmonary hypertension (POPH) have worse survival. Health disparities may contribute to these differences but have not been studied. We sought to...
7.
Lentine K, Lam N, Caliskan Y, Xiao H, Axelrod D, Costa S, et al.
Transplantation
. 2021 Apr;
106(3):666-675.
PMID: 33859148
Background: The incidence, risks, and outcomes associated with pulmonary hypertension (P-HTN) in the kidney transplant (KTx) population are not well described. Methods: We linked US transplant registry data with Medicare...
8.
DuBrock H, Runo J, Sadd C, Burger C, Cartin-Ceba R, Rosen C, et al.
Transplant Direct
. 2020 Nov;
6(12):e630.
PMID: 33204828
Methods: In this case series, we describe the characteristics and posttransplant outcomes of patients with treated POPH and an mPAP ≥35 mm Hg and pulmonary vascular resistance (PVR) <250 dynes-s-cm...
9.
Sadd C, Osman F, Li Z, Chybowski A, Decker C, Henderson B, et al.
Transplantation
. 2020 Apr;
105(2):346-353.
PMID: 32235258
Background: Portopulmonary hypertension is present in an estimated 5.3% to 8.5% of liver transplant candidates. Untreated, 5-year survival is estimated between 14% and 28%. Moderate-severe disease is a contraindication to...
10.
Forouzan O, Dinges E, Runo J, Keevil J, Eickhoff J, Francois C, et al.
Front Physiol
. 2019 Apr;
10:269.
PMID: 31001123
Pulmonary hypertension causes pulmonary artery (PA) stiffening, which overloads the right ventricle (RV). Since symptoms of pulmonary hypertension (PH) are exacerbated by exercise, exercise-induced PA stiffening is relevant to cardiopulmonary...